Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Onconova Therapeutics (NASDAQ: ONTX ) , a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the interim results of its late-stage metastatic pancreatic cancer study.
So what: According to Onconova's press release, which came out after the closing bell yesterday, Onconova is discontinuing its late-stage study of intravenous rigosertib in combination with Eli Lilly's Gemzar in treating front-line metastatic cancer. After reviewing the interim data from Onconova's Ontrak trial, the data safety monitoring board concluded that rigosertib in combination with Gemzar was unlikely to demonstrate an overall survival benefit over the placebo. There were, however, no safety issues with the drug.
Now what: Chalk up yet another failure for a metastatic pancreatic cancer drug. The good news here for Onconova is that it does have other ongoing clinical trials across three different drugs. The worrisome aspect, though, is that rigosertib is by far the most advanced of those experimental drugs being tested. The remaining trials -- as a first-line low risk and second-line high-risk treatment for myelodysplastic syndrome, and for head and neck cancer -- are as a monotherapy and not a combo drug, so there's still hope it will perform well in treating these specific cancer types. However, I'd be lying if I said I wasn't incredibly concerned about this lead drug following yesterday's announcement.
Here's the big growth opportunity you should be watching instead
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.